Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer

BACKGROUND: Osimertinib is an essential drug to treat non-small-cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation, and rebiopsy is necessary to detect this mutation. However, the significance of repeat rebiopsy in NSCLC patients whose first rebiopsy was T7...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Ichihara, Eiki, Hotta, Katsuyuki, Kubo, Toshio, Higashionna, Tsukasa, Ninomiya, Kiichiro, Ohashi, Kadoaki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Clinical Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6047679/
https://ncbi.nlm.nih.gov/pubmed/30034635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25705
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars